ZBD | $40,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026)
Certified by Founder
Lodge
ECCOGENE 诚益生物
start up
China
- Shanghai, Shanghai
- 12/06/2023
- Series B
- $25,000,000
Eccogene is a biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases.
Eccogene is specialized in disease biology, medicinal chemistry, and translational science to advance its novel and differentiated pipeline of drugs to address the unmet medical needs for metabolic and immune-related diseases.
- Industry Pharmaceutical Manufacturing
- Website http://www.eccogene.com/
- LinkedIn https://www.linkedin.com/company/eccogene/
Related People
Jingye ZhouCo Founder
China -
Shanghai
Experienced R&D leader with a demonstrated history of innovating high quality drug candidates in the biotechnology industry. Decades of experience in small molecule drug discovery and deep insight in metabolic diseases, immune metabolism, and cancer metabolism
Cubby | $63,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Cork Protocol | $5,500,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)
Mendra | $82,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
Antidote Legal | $5,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)